Biologics Manufacturing Companies to Remain the Most Sought-after Targets

Posted by Deevika on January 31st, 2019

There has been a significant rise in the number of mergers & acquisition activities in the contract manufacturing industry in recent years, with assets of drug manufacturing capabilities being the prime focus. Greater tendency of big pharma companies to build in-house production facilities apropos of biologics has resulted in outsourcing of packaging stages and secondary manufacturing activities. Recognizing the upward trend of drug formulation outsourcing and growth prospective of secondary manufacturing space, contract manufacturing organizations (CMOs) are enhancing their capacities and capabilities to win new business to venture in the pharma space. Biologics manufacturing companies, owing to their complex technologies, are projected to remain the most sought-after targets for acquisitions. Additionally, the prime focus of the acquirers remain on the CMOs, which are highly involved in analytical services, dose, and APIs-small molecule. Out of 130 acquisitions that happened during the period from 2015 to 2017, about 70% of service company acquirers were operating companies rather than investment firms. These valuable insights have been extracted from a report titled, “PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition” that is recently incorporated in the repository of Market Research Hub (MRH). The private equity firms or the CMOs owned by them acquired about 36% of the companies, while the other companies were acquired by the public companies.

Click here for Free Sample Report@        

PharmSource – M&A in the Contract Manufacturing Industry: A Gist of the Report

The primary aim of the report is to offer valuable insights on the mergers and acquisitions in contract manufacturing industry. The report aims at providing crucial data points of the industry to the CMOs, bio/pharma stakeholders, and stock analysts. Reliable sources have been employed to extract authentic data for the report. The report encompasses recent market trends, competitive landscape, performance standards, and strategic planning, which provide valuable market information to the CMOs. This comprehensive report offers competitive intelligence, market trends, and supplier performance standards to the stakeholders of pharma/bio. An analysis of target identification and performance standards of portfolio companies has been elaborated in the report for private equity (PE) and stock analysts. The report provides a visual assessment by providing 28 tables and figures to illustrate key trends and points that have influenced the contract manufacturing industry. The comprehensive study includes bio/pharmaceutical activities and development for the executives of supply chain to understand the effects of M&A activities on their sourcing preferences.

View Full Report with Table and Content@

PharmSource – M&A in the Contract Manufacturing Industry: Competitive Landscape

The in-depth study aims at helping the CMOs recognize the essence of M&A activities in the industry. The report offers an outlook on the M&A activities along with their valuations for the stakeholders of the industry.

The report profiles some leading players in the industry such as, 3SBio, ABC Laboratories, Abzena, Acacia Lifesciences, Absorption Systems, Accuratus Lab Services, Accucaps, Advantar Laboratories, Advanced BioScience Laboratories, Agere Pharmaceuticals, AGIC Capital, Ajinomoto, Aeras, and Akorn. An overview of these companies, along with their strategies, market share, and revenue size has been incorporated in the report.


Link To Directory
Top Searches - Trending Searches - New Articles - Top Articles - Trending Articles - Featured Articles - Top Members

Copyright 2020
679,603 total articles and counting.